Company Overview of Bayer Pharma AG
Bayer Pharma AG develops molecules for use in products and solutions for improving the health of humans, animals, and plants. The company focuses on prescription products for women’s healthcare and cardiology, and also on specialty therapeutics in the areas of oncology, hematology, and ophthalmology; markets contrast-enhanced diagnostic imaging equipment; provides allergy, analgesic, cardiovascular risk prevention, cough and cold, dermatology, foot care, gastrointestinal, nutritional, and sun care products; and focuses on high-value seeds, chemical and biological pest management solutions, customer service for modern and sustainable agriculture, and non-agricultural applications. It supports...
Founded in 1851
Key Executives for Bayer Pharma AG
Chief Executive Officer and Chairman of Management Board
Chief Financial Officer and Member of Management Board
Head of Specialized Therapeutics Business Area
Compensation as of Fiscal Year 2016.
Bayer Pharma AG Key Developments
Bayer Pharma AG Presents at BIO Trinity 2016, Apr-25-2016
Apr 22 16
Bayer Pharma AG Presents at BIO Trinity 2016, Apr-25-2016 . Venue: Novotel London West, 1 Shortlands, London W6 8DR, United Kingdom.
OncoMed Pharmaceuticals, Inc. Announces Selection of First Small Molecule Product Under Collaboration With Bayer Pharma AG
Sep 30 14
OncoMed Pharmaceuticals, Inc. announced selection of first small molecule product candidate targeting the Wnt pathway under collaboration with Bayer Pharma AG. The small molecule product candidate is advancing to preclinical development triggering a $2 million milestone payment to OncoMed. OncoMed and Bayer initiated joint discovery efforts to identify small molecule inhibitors of the Wnt pathway, a key cancer stem cell pathway, as part of the companies' collaboration initiated in 2010. This is the first small molecule inhibitor of a cancer stem cell pathway from the collaboration to enter preclinical development. Bayer will lead development and commercialization of Wnt small molecule product candidates.
Statute of Limitations Bars Claims Alleging Bayer Healthcare Pharmaceuticals Inc., Bayer Pharma AG and Bayer Healthcare Pharmaceuticals's IUD Perforated Patient's Uterus
Jul 25 14
Dismissing as time-barred claims arising from injuries a claimant suffered when an intrauterine device (IUD) migrated into her abdomen, the U.S. District Court for the Southern District of New York concluded that the statute of limitations began to run when the claimant should have been on notice of a possible connection between her injuries and the device. Bayer Healthcare Pharmaceuticals Inc., Bayer Pharma AG and Bayer Healthcare Pharmaceuticals (Bayer) manufactures Mirena, an IUD designed to prevent pregnancy for up to five years. On April 30, 2009, Dr. Cathy Carr inserted Mirena into a patient. In early July 2011, the patient began to experience nausea and vomiting. On July 7, 2011, Carr examined the patient and informed her the IUD may have moved. The patient went to the emergency room on July 8 and July 9, 2011. An examination revealed the IUD perforated the patient's uterus and migrated to her lower abdomen. The patient underwent emergency surgery to remove the IUD. She sued Bayer on Sept. 26, 2013. Bayer moved to dismiss on statute of limitations grounds. The district court observed that a two-year statute of limitations applied to the patient's defective design and manufacture, failure to warn and strict liability claims. The patient contended the statute of limitations did not begin to run until May 2013 when she saw a commercial that linked the injuries she suffered to Mirena. The district court disagreed. The statute of limitations for product liability claims accrues when a plaintiff knows or should know through the exercise of ordinary diligence that a product harmed her and she should inquire into her legal rights. By July 8 or 9, 2011, the patient knew she was injured and that the injury was in some way caused by Bayer's device. The patient, however, did not file suit until more than two years later so her products liability claims were untimely. The patient argued her suspicion that she was injured as a result of her doctor's negligence, as opposed to any negligence by Bayer, tolled the statute of limitations. The district court determined the existence of an alternative explanation for the patient's injuries did not mean the information the patient possessed on July 8 or 9, 2011, was insufficient to prompt her to investigate the device's role in causing her injuries.
Similar Private Companies By Industry
Recent Private Companies Transactions